// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Bedaquiline (BQ)-containing regimen at the programmatic level for MDR-TB: preliminary results

Sergey E. Borisov - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Bedaquiline

Late Breaking Abstract - The tuberculosis diagnostic evaluation cascade of care at microscopy centers linked to Xpert MTB/RIF hubs in Uganda

Katherine Farr - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Development Of Silent Brain Lesions In Pediatric Patients With Antibodies To Myelin Oligodendrocyte Glycoprotein

G. Fadda - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)

P. Vermersch - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

Ocrelizumab

Multiple Sclerosis Management And EDSS: A Great Start, But A Reason For Change Was Never So Apparent And Needed

J. Srinivasan - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

N/A

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation For Multiple Sclerosis

J. A. Cohen - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Efficacy Outcomes In Cladribine Tablets-treated Patients In CLARITY Were Similar Between Patients Who Did Vs. Did Not Enter CLARITY Extension

G. Comi - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

Long-term Reduction Of Relapse Rate And Confirmed Disability Progression After 6 Years Of Ocrelizumab Treatment In Patients With Relapsing MS

S. L. Hauser - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

Ocrelizumab

The Effect Of Cladribine Tablets In Patients With Relapsing-remitting Multiple Sclerosis Who Had Evidence Of Disease Activity In CLARITY

B. M. Greenberg - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Time To First Relapse Over The Duration Of Clarity And Clarity Extension In Patients Treated With Cladribine Tablets 3.5 Mg/kg Over Two Years

G. Giovannoni - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

Updated Safety Of Cladribine Tablets In The Treatment Of Patients With Multiple Sclerosis: Integrated Safety Analysis And Post-approval Data

S. Cook - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Effect Of Ozanimod On Circulating Leukocyte Subtypes In Patients With Relapsing Multiple Sclerosis: Results From A Phase 1 Study

S. Harris - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Ozanimod

Increased Naïve B Cells, M2 Macrophages, And Decreased Memory B And T Cells During Immune Repopulation In CLARITY Assessed By Immune Cell Deconvolution

G. Giovannoni - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Reduction Of Risk Of Secondary Progressive Multiple Sclerosis Within Two Years Of Treatment With Cladribine Tablets: An Analysis Of The CLARITY Study

P. Vermersch - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Multiple Sclerosis

Cladribine

Axonal Integrity by MRS at Baseline in the SPI2 Ph3 Trial of MD1003 (hdPB): Effect of Sex, Disease Burden, and Progressive MS Type

S. Narayanan - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

MD1003

Impact Of Eculizumab On Hospitalization Rates And Relapse Treatment In Patients With AQP4+ NMOSD: The Phase 3 PREVENT Study

M. Yountz - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Eculizumab

Impact Of Eculizumab On Quality Of Life In AQP4+ NMOSD: Findings From The PREVENT Study

A. Berthele - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Eculizumab

Long-term Safety And Effectiveness Of Eculizumab In Neuromyelitis Optica Spectrum Disorder

D. Wingerchuk - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Neuromyelitis optica

Eculizumab

Interference Of GI Symptoms With Daily Activities And Work Productivity In MS Patients Treated With Diroximel Fumarate Versus Dimethyl Fumarate

R. T. Naismith - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dimethyl fumarate

Clinical And Demographic Features Predict The Response To A Digital Treatment Designed To Improve Processing Speed In People With Multiple Sclerosis

W. Rowles - Americas Committee For Treatment and Research in Multiple Sclerosis (ACTRIMS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Copyright © 2026. QuantiNova All rights reserved